Literature DB >> 10991942

A positively charged loop on the surface of kallistatin functions to enhance tissue kallikrein inhibition by acting as a secondary binding site for kallikrein.

V C Chen1, L Chao, J Chao.   

Abstract

Kallistatin is a serine proteinase inhibitor (serpin) that specifically inhibits tissue kallikrein. The inhibitory activity of kallistatin is abolished upon heparin binding. The loop between the H helix and C2 sheet of kallistatin containing clusters of basic amino acid residues has been identified as a heparin-binding site. In this study, we investigated the role of the basic residues in this region in tissue kallikrein inhibition. Kallistatin mutants containing double Ala substitutions for these basic residues displayed a 70-80% reduction of association rate constants, indicating the importance of these basic residues in tissue kallikrein inhibition. A synthetic peptide derived from the sequence between the H helix and C2 sheet of kallistatin was shown to suppress the kallistatin-kallikrein interaction through competition for tissue kallikrein binding. To further evaluate the function of this loop, we used alpha1-antitrypsin, a non-heparin-binding serpin and slow tissue kallikrein inhibitor as a scaffold to engineer kallikrein inhibitors. An alpha1-antitrypsin chimera harboring the P3-P2' residues and a sequence homologous to the positively charged region between the H helix and C2 sheet of kallistatin acquired heparin-suppressed inhibitory activity toward tissue kallikrein and exhibited an inhibitory activity 20-fold higher than that of the other chimera, which contained only kallistatin's P3-P2' sequence, and 2300-fold higher than that of wild-type alpha1-antitrypsin. The alpha1-antitrypsin chimera with inhibitory characteristics similar to those of kallistatin demonstrates that the loop between the H helix and C2 sheet of kallistatin is crucial in tissue kallikrein inhibition, and this functional loop can be used as a module to enhance the inhibitory activity of a serpin toward tissue kallikrein. In conclusion, our results indicate that a positively charged loop between the H helix and C2 sheet of a serpin can accelerate the association of a serpin with tissue kallikrein by acting as a secondary binding site.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10991942     DOI: 10.1074/jbc.M005691200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  11 in total

1.  Kallistatin inhibits TGF-β-induced endothelial-mesenchymal transition by differential regulation of microRNA-21 and eNOS expression.

Authors:  Youming Guo; Pengfei Li; Grant Bledsoe; Zhi-Rong Yang; Lee Chao; Julie Chao
Journal:  Exp Cell Res       Date:  2015-07-05       Impact factor: 3.905

Review 2.  Kallistatin suppresses cancer development by multi-factorial actions.

Authors:  Julie Chao; Pengfei Li; Lee Chao
Journal:  Crit Rev Oncol Hematol       Date:  2017-03-14       Impact factor: 6.312

3.  Identification of Serpinb6b as a species-specific mouse granzyme A inhibitor suggests functional divergence between human and mouse granzyme A.

Authors:  Dion Kaiserman; Sarah E Stewart; Kim Plasman; Kris Gevaert; Petra Van Damme; Phillip I Bird
Journal:  J Biol Chem       Date:  2014-02-06       Impact factor: 5.157

4.  Interaction of heparin with internally quenched fluorogenic peptides derived from heparin-binding consensus sequences, kallistatin and anti-thrombin III.

Authors:  Daniel C Pimenta; Iseli L Nantes; Eduardo S de Souza; Bernard Le Bonniec; Amando S Ito; Ivarne L S Tersariol; Vitor Oliveira; Maria A Juliano; Luiz Juliano
Journal:  Biochem J       Date:  2002-09-01       Impact factor: 3.857

5.  Human kallistatin administration reduces organ injury and improves survival in a mouse model of polymicrobial sepsis.

Authors:  Pengfei Li; Grant Bledsoe; Zhi-Rong Yang; Hongkuan Fan; Lee Chao; Julie Chao
Journal:  Immunology       Date:  2014-06       Impact factor: 7.397

6.  Basic Residues of β-Sheet A Contribute to Heparin Binding and Activation of Vaspin (Serpin A12).

Authors:  David Ulbricht; Kathrin Oertwig; Kristin Arnsburg; Anja Saalbach; Jan Pippel; Norbert Sträter; John T Heiker
Journal:  J Biol Chem       Date:  2016-12-09       Impact factor: 5.157

Review 7.  Exosite determinants of serpin specificity.

Authors:  Peter G W Gettins; Steven T Olson
Journal:  J Biol Chem       Date:  2009-04-28       Impact factor: 5.157

8.  Kallistatin treatment attenuates lethality and organ injury in mouse models of established sepsis.

Authors:  Pengfei Li; Youming Guo; Grant Bledsoe; Zhi-Rong Yang; Hongkuan Fan; Lee Chao; Julie Chao
Journal:  Crit Care       Date:  2015-05-01       Impact factor: 9.097

Review 9.  Role of Kallistatin Treatment in Aging and Cancer by Modulating miR-34a and miR-21 Expression.

Authors:  Julie Chao; Youming Guo; Pengfei Li; Lee Chao
Journal:  Oxid Med Cell Longev       Date:  2017-06-28       Impact factor: 6.543

10.  Kallistatin reduces vascular senescence and aging by regulating microRNA-34a-SIRT1 pathway.

Authors:  Youming Guo; Pengfei Li; Lin Gao; Jingmei Zhang; Zhirong Yang; Grant Bledsoe; Eugene Chang; Lee Chao; Julie Chao
Journal:  Aging Cell       Date:  2017-05-24       Impact factor: 9.304

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.